TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TELA Bio (NASDAQ: TELA) announced that its Compensation Committee approved inducement restricted stock unit grants covering 14,250 shares to five newly hired employees with a grant date of January 20, 2026.

Rhea-AI Summary

TELA Bio (NASDAQ: TELA) announced that its Compensation Committee approved inducement restricted stock unit grants covering 14,250 shares to five newly hired employees with a grant date of January 20, 2026. The awards were made under the Nasdaq Rule 5635(c)(4) inducement exception as part of each hire's employment compensation. The restricted stock units will vest in equal annual installments over four years, subject to continued service through each vesting date.

Argus Jan 26 session

-0.98% close to close Open Argus

Details

News Market Reaction – TELA

On Jan 26, the first trading day after this news, TELA closed 0.98% below the previous close.

Data tracked by StockTitan Argus for the Jan 26 session.

Market Context

This announcement documents inducement equity grants of 14,250 restricted stock units to five new em...

Analysis

This announcement documents inducement equity grants of 14,250 restricted stock units to five new employees under Nasdaq Rule 5635(c)(4), vesting over four years. It continues a pattern of using equity-based compensation alongside prior financings, including a $13.0M registered direct offering and a $70.0M credit facility with associated warrants and an S-3 registering 2,000,000 resale shares. Investors may watch how ongoing equity usage and registered resale capacity interact with fundamentals like revenue growth and cash needs.

Key Figures

Inducement RSUs: 14,250 shares New hires: 5 employees Vesting term: 4 years +5 more

Inducement RSUs

14,250 shares

RSU inducement grants to five new employees, Grant Date January 20, 2026

New hires

5 employees

Recipients of Nasdaq Rule 5635(c)(4) inducement RSU awards

Vesting term

4 years

RSUs vest in equal annual installments over four years

Registered resale shares

2,000,000 shares

Shares registered on Form S-3 for resale by Perceptive Credit Holdings V, LP

Equity offering size

$13.0M

Gross proceeds from Nov 13, 2025 registered direct offering

Q3 2025 revenue

$20.7M

Third quarter 2025 financial results

Credit facility

$70.0M

Senior secured term loan with Perceptive; initial $60.0M drawn

Warrant shares

2,000,000 + 333,333

Warrants issued to Perceptive under credit facility terms

Historical Context

5 past events · Latest: Dec 12

5 events

1. Dec 12

   Inducement grants

   24h Move

   -1.7%

   RSU inducement grants totaling 3,600 shares to new hires over four years.

2. Nov 19

   Conference participation

   24h Move

   -8.5%

   Announcement of participation in Piper Sandler healthcare conference with webcast access.

3. Nov 17

   Inducement grants

   24h Move

   +14.1%

   Nasdaq 5635(c)(4) awards of 30,200 RSUs and 25,000 stock options to new hires.

4. Nov 13

   Equity offering

   24h Move

   -2.6%

   Pricing of $13.0M registered direct offering of common stock and pre-funded warrants.

5. Nov 13

   Earnings & financing

   24h Move

   -2.6%

   Q3 2025 results with $20.7M revenue, improved losses, and new $70M credit facility.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units, nasdaq rule 5635(c)(4), vesting

3 terms

restricted stock units financial

"approved inducement grants of restricted stock units covering 14,250 shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq rule 5635(c)(4) regulatory

"The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception"

NASDAQ Rule 5635(c)(4) is a listing standard that requires a company to obtain shareholder approval before issuing a substantial number of new shares or convertible securities in certain financing or insider-related transactions that would materially dilute existing holders. It matters to investors because the vote gives shareholders a check on deals that could significantly change ownership stakes or voting power—like a homeowners’ association approving a major renovation that affects the whole neighborhood’s value.

vesting financial

"The restricted stock units will vest in equal annual installments over four years"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 14,250 shares of its common stock to five newly-hired employees, with a grant date of January 20, 2026 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.

The restricted stock units will vest in equal annual installments over four years, subject to each individual's continued service with TELA Bio through the applicable vesting dates.

About TELA Bio, Inc.

TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.

Caution Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.

Investor Contact
Louisa Smith
ir@telabio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did TELA (NASDAQ: TELA) announce on January 23, 2026 about inducement grants?

TELA announced restricted stock unit grants covering 14,250 shares to five new hires, granted as inducements with a January 20, 2026 grant date.

Under which Nasdaq rule were TELA's inducement restricted stock units granted?

The awards were granted under the Nasdaq Rule 5635(c)(4) inducement exception as part of each individual's employment compensation.

How will the TELA restricted stock units vest for the newly hired employees?

The restricted stock units will vest in equal annual installments over four years, subject to continued service through each vesting date.

How many employees received inducement grants from TELA and how many shares were covered?

Five newly hired employees received inducement grants covering a total of 14,250 shares of common stock.

What is the effective grant date for the TELA inducement awards?

The restricted stock units have a grant date of January 20, 2026.

Do TELA's inducement grants require continued employment to vest?

Yes, vesting is subject to each individual's continued service with TELA through the applicable vesting dates.